Hong Kong, China

HUTCHMED, a Hong Kong-based biopharmaceutical company, is on track to become a global leader in the discovery, development, and commercialisation of innovative, highly selective oral tyrosine kinase inhibitor therapies for oncology and immunological indications.

Investment Perspective

HUTCHMED’s clearly articulated strategy is delivering, with consistent clinical and commercial execution marking its continuing transition from a development stage company into a profitable commercial organisation. Growth in Oncology/ Immunology revenues, defined investment priorities, and a global partnering strategy should all contribute to achieving a FY25 breakeven target. HUTCHMED aims to expand its marketed portfolio of oncology drugs in China from three to six or seven by FY25, addressing blood disorders as well as solid tumours. First global launch of an in-house product, by partner Takeda, could occur in 2024, subject to a positive FDA approval decision in November. Our updated HUTCHMED valuation is $5.74bn ($32.95 per ADS), £4.78bn and HK$44.75n (549p or HK$51.40 per share).

Market information



FY23 results point to strong financials and fundamentals
Lighthouse | 29 Feb 2024
Fruquintinib clinical and commercial updates
Lighthouse | 12 Feb 2024
Landmark FDA approval for fruquintinib
Lighthouse | 13 Nov 2023

Recent News

FY23 results & business update
28 Feb 2024
Phase III fruquintinib data in 2L gastric cancer presented at ASCO Plenary Series Session
07 Feb 2024
Inmagene exercises option to two candidates
02 Feb 2024
Elunate (fruquintinib) Hong Kong Marketing Approval for treatment of mCRC
30 Jan 2024